Huntington's Disease - Pipeline Review, H2 2015

Date: November 30, 2015
Pages: 311
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H7E25AAB8A2EN
Leaflet:

Download PDF Leaflet

Huntington's Disease - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Huntington's Disease - Pipeline Review, H2 2015’, provides an overview of the Huntington's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Huntington's Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Huntington's Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Huntington's Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Huntington's Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Huntington's Disease Overview
Therapeutics Development
Pipeline Products for Huntington's Disease - Overview
Pipeline Products for Huntington's Disease - Comparative Analysis
Huntington's Disease - Therapeutics under Development by Companies
Huntington's Disease - Therapeutics under Investigation by Universities/Institutes
Huntington's Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Huntington's Disease - Products under Development by Companies
Huntington's Disease - Products under Investigation by Universities/Institutes
Huntington's Disease - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
AFFiRiS AG
Alnylam Pharmaceuticals, Inc.
Angita B.V.
Astellas Pharma Inc.
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
BioMarin Pharmaceutical Inc.
BrainStorm Cell Therapeutics Inc.
Chong Kun Dang Pharmaceutical Corp.
Chronos Therapeutics Limited
EncephRx, Inc.
Evotec AG
Galenea Corp.
Genervon Biopharmaceuticals, LLC
Genethon
Ipsen S.A.
Isis Pharmaceuticals, Inc.
Kadmon Corporation, LLC
KineMed, Inc.
Living Cell Technologies Limited
Medesis Pharma S.A.
Neuralstem, Inc.
Neurimmune Holding AG
NeuroNascent, Inc.
New World Laboratories, Inc.
nLife Therapeutics, S.L.
NsGene A/S
Omeros Corporation
Oryzon Genomics S.A.
Pfizer Inc.
PharmatrophiX, Inc.
Prana Biotechnology Limited
Provid Pharmaceuticals, Inc.
QR Pharma, Inc.
Raptor Pharmaceuticals Inc
reMYND NV
RestorGenex Corporation
Rhenovia Pharma Limited
Sangamo BioSciences, Inc.
SOM Innovation Biotech SL
Teva Pharmaceutical Industries Limited
TyrNovo Ltd.
Ultragenyx Pharmaceutical Inc.
uniQure N.V.
Vaccinex, Inc.
Vertex Pharmaceuticals Incorporated
VistaGen Therapeutics, Inc.
VivaCell Biotechnology Espana S.L.
Voyager Therapeutics, Inc.
Vybion, Inc.
Zenobia Therapeutics, Inc.
Huntington's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AK-7 - Drug Profile
ALN-HTT - Drug Profile
Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile
Antisense Oligonucleotide to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile
ASP-2905 - Drug Profile
AV-101 - Drug Profile
BN-82451 - Drug Profile
Carbenoxolone sodium - Drug Profile
Cell Therapy for Huntington’s Disease - Drug Profile
CNB-001 - Drug Profile
CP-2 - Drug Profile
cysteamine DR - Drug Profile
DC-012 - Drug Profile
dipraglurant IR - Drug Profile
dutetrabenazine ER - Drug Profile
ED-11 - Drug Profile
ENC-1001 - Drug Profile
fisetin - Drug Profile
Gene Therapy to Activate CNTF for Huntington’s Disease - Drug Profile
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
GM-609 - Drug Profile
HSB-13 - Drug Profile
INT-41 - Drug Profile
ISIS-HTTRx - Drug Profile
JM-6 - Drug Profile
JR-100 - Drug Profile
JRP-655 - Drug Profile
JRP-900 - Drug Profile
KL-00148 - Drug Profile
laquinimod sodium - Drug Profile
lithium citrate - Drug Profile
LM11A-31BHS - Drug Profile
Memantine Nitrone - Drug Profile
MP-101 - Drug Profile
NI-302 - Drug Profile
NNI-362 - Drug Profile
NNI-370 - Drug Profile
noscapine - Drug Profile
NP-42T - Drug Profile
NsG-33 - Drug Profile
NSI-566 - Drug Profile
NT-219 - Drug Profile
NTCELL - Drug Profile
NWL-154 - Drug Profile
OGCx-833 - Drug Profile
OMS-527 - Drug Profile
ORY-2001 - Drug Profile
OXD-5 - Drug Profile
PBF-999 - Drug Profile
PBT-2 - Drug Profile
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile
PF-02545920 - Drug Profile
Posiphen - Drug Profile
pridopidine hydrochloride - Drug Profile
PRO-289 - Drug Profile
RDC-5 - Drug Profile
Recombinant Protein for Alzheimer's Disease and Huntington's Disease - Drug Profile
RES-529 - Drug Profile
Rhedar - Drug Profile
RNAi Gene Therapy to Inhibit Huntingtin for Huntington’s Disease - Drug Profile
RO-5461861 - Drug Profile
Rycal - Drug Profile
Small Molecule for Huntington's Disease - Drug Profile
Small Molecule for Huntington’s Disease - Drug Profile
Small Molecule for Huntington’s Disease - Drug Profile
Small Molecule for Huntington’s Disease - Drug Profile
Small Molecule for Parkinson's Disease and Huntington's Disease - Drug Profile
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile
Small Molecule to Antagonize NMDA receptor for Huntington's Disease - Drug Profile
Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease - Drug Profile
Small Molecule to Inhibit PDE10 for Schizophrenia and Huntington's Disease - Drug Profile
Small molecules for Huntington Disease - Drug Profile
Small Molecules for Huntington's Disease - Drug Profile
Small Molecules to Activate HSF-1 for Huntington's Disease - Drug Profile
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile
Small Molecules to Antagonize NMDA Receptor for Neurodegenerative Disorders - Drug Profile
Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile
Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile
Small Molecules to Inhibit Caspase-6 for Huntingtons Disease - Drug Profile
Small Molecules to Inhibit DREAM Protein for Huntington's Disease - Drug Profile
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Small Molecules to Inhibit LSD-1 And MAO-B for Huntington Disease - Drug Profile
Small Molecules to Inhibit PDE-10A for Huntington's Disease - Drug Profile
Small Molecules to Target Free Radical for Huntington's Disease - Drug Profile
SNB-2401 - Drug Profile
SNB-4050 - Drug Profile
SOM-3355 - Drug Profile
SRX-246 - Drug Profile
Stem Cell Therapy for Huntington’s Disease - Drug Profile
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile
Stem Cell Therapy to Activate BDNF for Huntington’s Disease - Drug Profile
Stem Cell Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile
Synthetic Peptide to Inhibit Calmodulin for Huntington's Disease - Drug Profile
Synthetic Peptides for Central Nervous System Disorders - Drug Profile
Synthetic Peptides for Huntington's Disease - Drug Profile
UX-007 - Drug Profile
Vaccine for Huntington's Disease - Drug Profile
VCE-003 - Drug Profile
VCE-0032 - Drug Profile
VX-15 - Drug Profile
VYHTT-01 - Drug Profile
WT-501 - Drug Profile
XJB-5131 - Drug Profile
Huntington's Disease - Recent Pipeline Updates
Huntington's Disease - Dormant Projects
Huntington's Disease - Discontinued Products
Huntington's Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Huntington's Disease, H2 2015
Number of Products under Development for Huntington's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Development by Companies, H2 2015 (Contd.3)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Development by Companies, H2 2015 (Contd.4)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd.1)
Huntington's Disease - Pipeline by Addex Therapeutics Ltd, H2 2015
Huntington's Disease - Pipeline by AFFiRiS AG, H2 2015
Huntington's Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Huntington's Disease - Pipeline by Angita B.V., H2 2015
Huntington's Disease - Pipeline by Astellas Pharma Inc., H2 2015
Huntington's Disease - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015
Huntington's Disease - Pipeline by BioCrea GmbH, H2 2015
Huntington's Disease - Pipeline by BioMarin Pharmaceutical Inc., H2 2015
Huntington's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015
Huntington's Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015
Huntington's Disease - Pipeline by Chronos Therapeutics Limited, H2 2015
Huntington's Disease - Pipeline by EncephRx, Inc., H2 2015
Huntington's Disease - Pipeline by Evotec AG, H2 2015
Huntington's Disease - Pipeline by Galenea Corp., H2 2015
Huntington's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015
Huntington's Disease - Pipeline by Genethon, H2 2015
Huntington's Disease - Pipeline by Ipsen S.A., H2 2015
Huntington's Disease - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Huntington's Disease - Pipeline by Kadmon Corporation, LLC, H2 2015
Huntington's Disease - Pipeline by KineMed, Inc., H2 2015
Huntington's Disease - Pipeline by Living Cell Technologies Limited, H2 2015
Huntington's Disease - Pipeline by Medesis Pharma S.A., H2 2015
Huntington's Disease - Pipeline by Neuralstem, Inc., H2 2015
Huntington's Disease - Pipeline by Neurimmune Holding AG, H2 2015
Huntington's Disease - Pipeline by NeuroNascent, Inc., H2 2015
Huntington's Disease - Pipeline by New World Laboratories, Inc., H2 2015
Huntington's Disease - Pipeline by nLife Therapeutics, S.L., H2 2015
Huntington's Disease - Pipeline by NsGene A/S, H2 2015
Huntington's Disease - Pipeline by Omeros Corporation, H2 2015
Huntington's Disease - Pipeline by Oryzon Genomics S.A., H2 2015
Huntington's Disease - Pipeline by Pfizer Inc., H2 2015
Huntington's Disease - Pipeline by PharmatrophiX, Inc., H2 2015
Huntington's Disease - Pipeline by Prana Biotechnology Limited, H2 2015
Huntington's Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2015
Huntington's Disease - Pipeline by QR Pharma, Inc., H2 2015
Huntington's Disease - Pipeline by Raptor Pharmaceuticals Inc, H2 2015
Huntington's Disease - Pipeline by reMYND NV, H2 2015
Huntington's Disease - Pipeline by RestorGenex Corporation, H2 2015
Huntington's Disease - Pipeline by Rhenovia Pharma Limited, H2 2015
Huntington's Disease - Pipeline by Sangamo BioSciences, Inc., H2 2015
Huntington's Disease - Pipeline by SOM Innovation Biotech SL, H2 2015
Huntington's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Huntington's Disease - Pipeline by TyrNovo Ltd., H2 2015
Huntington's Disease - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015
Huntington's Disease - Pipeline by uniQure N.V., H2 2015
Huntington's Disease - Pipeline by Vaccinex, Inc., H2 2015
Huntington's Disease - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Huntington's Disease - Pipeline by VistaGen Therapeutics, Inc., H2 2015
Huntington's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Huntington's Disease - Pipeline by Voyager Therapeutics, Inc., H2 2015
Huntington's Disease - Pipeline by Vybion, Inc., H2 2015
Huntington's Disease - Pipeline by Zenobia Therapeutics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Huntington's Disease Therapeutics - Recent Pipeline Updates, H2 2015
Huntington's Disease - Dormant Projects, H2 2015
Huntington's Disease - Dormant Projects (Contd.1), H2 2015
Huntington's Disease - Dormant Projects (Contd.2), H2 2015
Huntington's Disease - Dormant Projects (Contd.3), H2 2015
Huntington's Disease - Dormant Projects (Contd.4), H2 2015
Huntington's Disease - Dormant Projects (Contd.5), H2 2015
Huntington's Disease - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Huntington's Disease, H2 2015
Number of Products under Development for Huntington's Disease - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Addex Therapeutics Ltd
AFFiRiS AG
Alnylam Pharmaceuticals, Inc.
Angita B.V.
Astellas Pharma Inc.
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
BioMarin Pharmaceutical Inc.
BrainStorm Cell Therapeutics Inc.
Chong Kun Dang Pharmaceutical Corp.
Chronos Therapeutics Limited
EncephRx, Inc.
Evotec AG
Galenea Corp.
Genervon Biopharmaceuticals, LLC
Genethon
Ipsen S.A.
Isis Pharmaceuticals, Inc.
Kadmon Corporation, LLC
KineMed, Inc.
Living Cell Technologies Limited
Medesis Pharma S.A.
Neuralstem, Inc.
Neurimmune Holding AG
NeuroNascent, Inc.
New World Laboratories, Inc.
nLife Therapeutics, S.L.
NsGene A/S
Omeros Corporation
Oryzon Genomics S.A.
Pfizer Inc.
PharmatrophiX, Inc.
Prana Biotechnology Limited
Provid Pharmaceuticals, Inc.
QR Pharma, Inc.
Raptor Pharmaceuticals Inc
reMYND NV
RestorGenex Corporation
Rhenovia Pharma Limited
Sangamo BioSciences, Inc.
SOM Innovation Biotech SL
Teva Pharmaceutical Industries Limited
TyrNovo Ltd.
Ultragenyx Pharmaceutical Inc.
uniQure N.V.
Vaccinex, Inc.
Vertex Pharmaceuticals Incorporated
VistaGen Therapeutics , Inc.
VivaCell Biotechnology Espana S.L.
Voyager Therapeutics, Inc.
Vybion, Inc.
Zenobia Therapeutics, Inc.
Skip to top


Alzheimer's Disease - Pipeline Review, H2 2016 US$ 2,500.00 Aug, 2016 · 1284 pages
Gaucher's Disease - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 86 pages

Ask Your Question

Huntington's Disease - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: